Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $19.00 by Analysts at Guggenheim

Sarepta Therapeutics (NASDAQ:SRPT) had its price target dropped by equities research analysts at Guggenheim from $22.00 to $19.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target indicates a potential upside of 5.09% from the stock’s current price.

SRPT has been the topic of several other reports. Bank of America lifted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a report on Wednesday, October 22nd. BMO Capital Markets raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Monday, September 22nd. Oppenheimer raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $30.00 to $37.00 in a report on Tuesday, July 29th. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Finally, Baird R W cut Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have issued a Sell rating to the company. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus target price of $33.83.

Sarepta Therapeutics Stock Up 11.6%

Shares of SRPT traded up $1.88 during midday trading on Wednesday, reaching $18.08. 3,737,322 shares of the stock were exchanged, compared to its average volume of 6,312,258. The company has a market capitalization of $1.77 billion, a P/E ratio of -20.87 and a beta of 0.52. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $138.81. The company’s 50 day moving average is $20.32 and its two-hundred day moving average is $26.28.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business had revenue of $399.36 million during the quarter, compared to analysts’ expectations of $331.51 million. During the same period last year, the company earned $0.62 earnings per share. The firm’s revenue was down 14.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Ancora Advisors LLC increased its holdings in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $33,000. Banque Transatlantique SA purchased a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $44,000. Pandora Wealth Inc. purchased a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $45,000. Finally, Brooklyn Investment Group raised its stake in Sarepta Therapeutics by 450.4% in the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.